The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic DiseaseFunding Funding was provided by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Project Number 288034826 – IRTG: 2251 (SRB).
Currently, we are experiencing a true pandemic of a communicable disease by the virus SARS-CoV-2 holding the whole world firmly in its grasp. Amazingly and unfortunately, this virus uses a metabolic and endocrine pathway via ACE2 to enter our cells causing damage and disease. Our international research training programme funded by the German Research Foundation has a clear mission to train the best students wherever they may come from to learn to tackle the enormous challenges of diabetes and its complications for our society. A modern training programme in diabetes and metabolism does not only involve a thorough understanding of classical physiology, biology and clinical diabetology but has to bring together an interdisciplinary team. With the arrival of the coronavirus pandemic, this prestigious and unique metabolic training programme is facing new challenges but also new opportunities. The consortium of the training programme has recognized early on the need for a guidance and for practical recommendations to cope with the COVID-19 pandemic for the community of patients with metabolic disease, obesity and diabetes. This involves the optimal management from surgical obesity programmes to medications and insulin replacement. We also established a global registry analyzing the dimension and role of metabolic disease including new onset diabetes potentially triggered by the virus. We have involved experts of infectious disease and virology to our faculty with this metabolic training programme to offer the full breadth and scope of expertise needed to meet these scientific challenges. We have all learned that this pandemic does not respect or heed any national borders and that we have to work together as a global community. We believe that this transCampus metabolic training programme provides a prime example how an international team of established experts in the field of metabolism can work together with students from all over the world to address a new pandemic.
Received: 22 January 2021
Accepted after revision: 23 January 2021
02 March 2021 (online)
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Bornstein SR, Dalan R, Hopkins D. et al. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol 2020; 16: 297-298
- 2 Mallapaty S. Mounting clues suggest the coronavirus might trigger diabetes. Nature 2020; 583: 16-17
- 3 Mitchell F. transCampus London-Dresden: A new model for international collaborative research. Lancet Diabetes Endocrinol 2017; 5: 939
- 4 Ludwig B, Ludwig S, Steffen A. et al. Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes. Proc Natl Acad Sci USA 2017; 114: 11745-11750
- 5 Cohrs CM, Panzer JK, Drotar DM. et al. Dysfunction of persisting beta cells is a key feature of early type 2 diabetes pathogenesis. Cell Rep 2020; 31: 107469
- 6 Bornstein SR, Rubino F, Khunti K. et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020; 8: 546-550
- 7 Rubino F, Amiel SA, Zimmet P. et al. New-Onset Diabetes in COVID-19. N Engl J Med 2020; 383: 789-790
- 8 Hollstein T, Schulte DM, Schulz J. et al. Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: A case report. Nat Metab 2020; 2: 1021-1024
- 9 Steenblock C, Todorov V, Kanczkowski W. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. Mol Psychiatry 2020; 25: 1611-1617
- 10 Barthel A, Mohanraj K, Biener AM. et al. Metabolic Syndrome and COVID-19: Endocrine-immune vascular interactions shape the clinical course. Endocrinology 2020; 161 bqaa131
- 11 Tonn T, Corman VM, Johnsen M. et al. Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma. Lancet Microbe 2020; 1: e63
- 12 Mayr M, Gutmann C, Takov K. et al. SARS-CoV-2 RNAemia and proteomic biomarker trajectory inform prognostication in COVID-19 patients admitted to intensive care. Preprint, DOI: 10.21203/rs.3.rs-101592/v1.